Gregory Gaspard, MD
Gastroenterology · Baton Rouge, LANPI 1982882874
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $69,987 of the $86,231 with a category attached, or 81.2%. Johnson & Johnson accounts for 87.8% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $72,339, more than ten times the $785 reported in 2019. Among gastroenterology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 132 payments — averaging $653.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$76K
- Pfizer$7K
- Janssen Research & Development, LLC$949
- Bristol Myers Squibb$582
- AbbVie$423
- Janssen Scientific Affairs, LLC$274
- plus $915 from 11 others
Across 59 payments — averaging $66,678 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$3.9M
- Eli Lilly$32K
- Janssen Research & Development, LLC$23K
- Boehringer Ingelheim$19K
What the payments were for
- Speaking & faculty fees$69,98781%
- Travel & lodging$11,52613%
- Food & beverage$4,6685%
- Education$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 71 | $75,688 |
| Pfizer | 9 | $7,402 |
| Janssen Research & Development, LLC | 6 | $949 |
| Bristol Myers Squibb | 8 | $582 |
| AbbVie(2 entities) | 12 | $423 |
| Janssen Scientific Affairs, LLC | 3 | $274 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $219 |
| Boehringer Ingelheim | 1 | $145 |
| Gilead | 1 | $124 |
| E.r. Squibb & Sons, L.L.C. | 1 | $116 |
| Boston Scientific | 2 | $79 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $64 |
| Shire North American Group Inc | 3 | $55 |
| Shionogi Inc | 2 | $45 |
| UCB, Inc. | 2 | $39 |
| Sandoz | 1 | $19 |
| Intercept Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$86,231 in reported general payments places this provider in the 95th percentile of 254 gastroenterology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 109 | $2,940,824 |
| Humira(Cf) PenAdalimumab | 54 | $656,590 |
| GattexTeduglutide | 11 | $505,804 |
| Skyrizi On-BodyRisankizumab-Rzaa | 11 | $228,389 |
| RemicadeInfliximab | 19 | $205,085 |
| EntyvioVedolizumab | 19 | $164,602 |
| RinvoqUpadacitinib | 15 | $144,174 |
| Entyvio PenVedolizumab | 21 | $122,717 |
| CreonLipase/Protease/Amylase | 18 | $16,961 |
| Mesalamine | 41 | $12,203 |
| LinzessLinaclotide | 19 | $10,304 |
| Balsalazide Disodium | 41 | $6,177 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 68 | $4,521 |
| Colestipol Hcl | 12 | $2,598 |
| Sucralfate | 13 | $1,265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara, Remicade | $75,688 | $3,145,910128 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gattex, Entyvio | $219 | $670,40630 claims |
| AbbVieRinvoq, Creon, Linzess | $423 | $171,43952 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 254 gastroenterology providers in Louisiana.
Other gastroenterology in Baton Rouge
- Jonathon ChapmanBaton Rouge$998K
- Gia LandryBaton Rouge$511K
- Neelima ReddyBaton Rouge$23K
- Ronald LeoBaton Rouge$9K
- Conar FittonKenner$955K
- Charles MonierThibodaux$448K
- Nathaniel RanneyCovington$392K
- Georges CatinisMetairie$346K
- Humberto AguilarShreveport$313K
- Sarah GloverNew Orleans$274K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.